BioSpace News Archive

G1 Therapeutics, Inc., a clinical-stage oncology company, announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2020 on Wednesday, November 4, 2020 at 4:30 p.m. ET.

MediWound Ltd., a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced it has completed the enrollment stage of its NexoBrid® Phase 3 pediatric clinical study.

Neovasc Inc. announced that the United States Food and Drug Administration’s Circulatory System Devices Advisory Panel voted 14 to 4 “in favor” that the Neovasc Reducer™ is safe when used as intended, and voted 1 to 17 “against” on the issue of a reasonable assurance of effectiveness.

PolyPid Ltd., a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, announced that it will report its third quarter 2020 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 11, 2020.

Arcline Investment Management (“Arcline”), a growth-oriented private equity firm, today announced that it has acquired a controlling stake in SYNEO from Rockwood Equity. SYNEO is a vertically-integrated machine, tooling and services company focused on the interventional medical device industry as well as specialty “pres